Amorfix receives support from Canadian government to accelerate development of blood test for Alzheimer's disease

21-Dec-2006

Individually packed chromatography columns for maximum efficiency

Biometra TAdvanced – Benefit from More Than 30 Years of Experience in PCR

ChemiDoc Go: A compact, precise imager for Advanced Western Blotting

Amorfix Life Sciences Ltd. announced that in addition to their own investment, the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) will share in the research and development of the company's proposed diagnostic test for Alzheimer's disease, EP-AD(tm), via a contribution of $322,000.

The NRC-IRAP support will be focused on the extension of Amorfix's patent-pending Epitope Protection (EP) technology platform to the diagnosis of Alzheimer's disease, using a standard blood sample. NRC-IRAP is a federal government program that provides a range of both technical and business oriented advisory services along with potential financial support to growth-oriented Canadian small and medium-sized enterprises.

https://www.bionity.com/en/news/60327/amorfix-receives-support-from-canadian-government-to-accelerate-development-of-blood-test-for-alzheimer-s-disease.html